- Home
- VMO vs PHAR Comparison
VMO vs PHAR Comparison
Compare VMO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMO
- PHAR
- Stock Information
- Founded
- VMO 1992
- PHAR 1988
- Country
- VMO United States
- PHAR Netherlands
- Employees
- VMO N/A
- PHAR N/A
- Industry
- VMO Trusts Except Educational Religious and Charitable
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- VMO Finance
- PHAR Health Care
- Exchange
- VMO Nasdaq
- PHAR Nasdaq
- Market Cap
- VMO 611.0M
- PHAR 718.1M
- IPO Year
- VMO N/A
- PHAR N/A
- Fundamental
- Price
- VMO $9.07
- PHAR $10.45
- Analyst Decision
- VMO
- PHAR Strong Buy
- Analyst Count
- VMO 0
- PHAR 3
- Target Price
- VMO N/A
- PHAR $30.00
- AVG Volume (30 Days)
- VMO 254.7K
- PHAR 2.6K
- Earning Date
- VMO 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- VMO 4.39%
- PHAR N/A
- EPS Growth
- VMO N/A
- PHAR N/A
- EPS
- VMO N/A
- PHAR N/A
- Revenue
- VMO N/A
- PHAR $320,708,000.00
- Revenue This Year
- VMO N/A
- PHAR $13.31
- Revenue Next Year
- VMO N/A
- PHAR $7.68
- P/E Ratio
- VMO N/A
- PHAR N/A
- Revenue Growth
- VMO N/A
- PHAR 24.13
- 52 Week Low
- VMO $7.86
- PHAR $6.65
- 52 Week High
- VMO $9.87
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- VMO 42.63
- PHAR 47.51
- Support Level
- VMO $9.03
- PHAR $10.41
- Resistance Level
- VMO $9.08
- PHAR $11.50
- Average True Range (ATR)
- VMO 0.06
- PHAR 0.32
- MACD
- VMO 0.00
- PHAR -0.17
- Stochastic Oscillator
- VMO 34.21
- PHAR 2.26
About VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.